Published in Cancer Immunol Res on July 01, 2014
Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med (2015) 1.42
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J (2015) 1.00
Prelude to oral microbes and chronic diseases: past, present and future. Microbes Infect (2015) 0.92
Myeloid-derived suppressor cells and tumor escape from immune surveillance. Semin Immunopathol (2016) 0.84
The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev (2017) 0.80
Hypoxia-inducible factors as molecular targets for liver diseases. J Mol Med (Berl) (2016) 0.79
CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma. Am J Transl Res (2015) 0.79
αβ TCR-mediated recognition: relevance to tumor-antigen discovery and cancer immunotherapy. Cancer Immunol Res (2015) 0.78
Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model. Oncotarget (2015) 0.78
A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer. Curr Opin Pharmacol (2016) 0.77
Alternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5'-nucleotidase (CD73). Mol Biol Cell (2014) 0.76
Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest (2017) 0.76
Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression. Oncotarget (2016) 0.75
Oxygenation to improve cancer vaccines, adoptive cell transfer and blockade of immunological negative regulators. Oncoimmunology (2015) 0.75
Prostaglandin E2-mediated adenosinergic effects on CD14(+) cells: Self-amplifying immunosuppression in cancer. Oncoimmunology (2016) 0.75
Potassium channels of T lymphocytes take center stage in the fight against cancer. J Immunother Cancer (2017) 0.75
A2A adenosine receptors control pancreatic dysfunction in high-fat-diet induced obesity. FASEB J (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Hypoxia-inducible factors in physiology and medicine. Cell (2012) 8.16
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature (2002) 6.50
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci U S A (2008) 4.79
Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer (2008) 4.71
Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol (2004) 4.28
A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A (2006) 4.25
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev (2011) 4.16
Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J Clin Invest (2002) 4.05
Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation (2007) 3.65
T regulatory and primed uncommitted CD4 T cells express CD73, which suppresses effector CD4 T cells by converting 5'-adenosine monophosphate to adenosine. J Immunol (2006) 3.40
Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nat Rev Immunol (2005) 3.21
Physiological roles for ecto-5'-nucleotidase (CD73). Purinergic Signal (2006) 2.98
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood (1997) 2.67
The 'danger' sensors that STOP the immune response: the A2 adenosine receptors? Trends Immunol (2005) 2.43
Cellular and humoral immunity to different types of human neoplasms. Nature (1968) 2.40
Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol (2005) 2.36
The role of the transcription factor CREB in immune function. J Immunol (2010) 2.23
CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res (2010) 2.13
CD39 and CD73 in immunity and inflammation. Trends Mol Med (2013) 2.08
CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res (2011) 2.03
Identification of ectonucleotidases CD39 and CD73 in innate protection during acute lung injury. J Immunol (2007) 2.03
Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury. J Clin Invest (2012) 2.00
The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. Cancer Res (1997) 1.95
Chimeric antigen receptor therapy for cancer. Annu Rev Med (2013) 1.94
Staphylococcus aureus synthesizes adenosine to escape host immune responses. J Exp Med (2009) 1.85
Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res (2008) 1.84
Memory of extracellular adenosine A2A purinergic receptor-mediated signaling in murine T cells. J Biol Chem (1997) 1.76
Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med (1987) 1.75
Adenosine receptors as drug targets--what are the challenges? Nat Rev Drug Discov (2013) 1.74
T regulatory cells: hypoxia-adenosinergic suppression and re-direction of the immune response. Trends Immunol (2009) 1.74
Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med (Berl) (2012) 1.67
Targeted deletion of HIF-1alpha gene in T cells prevents their inhibition in hypoxic inflamed tissues and improves septic mice survival. PLoS One (2007) 1.61
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A (2013) 1.54
Ipilimumab (Yervoy) and the TGN1412 catastrophe. Immunobiology (2011) 1.53
CD73: a novel target for cancer immunotherapy. Cancer Res (2010) 1.52
Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1alpha -deficient chimeric mice. Proc Natl Acad Sci U S A (2002) 1.52
Patterns of A2A extracellular adenosine receptor expression in different functional subsets of human peripheral T cells. Flow cytometry studies with anti-A2A receptor monoclonal antibodies. Mol Pharmacol (1999) 1.51
Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice. Biochem J (2001) 1.49
Hypoxia-inducible factor-1α-dependent protection from intestinal ischemia/reperfusion injury involves ecto-5'-nucleotidase (CD73) and the A2B adenosine receptor. J Immunol (2011) 1.48
Antigen receptor-regulated exocytosis in cytotoxic T lymphocytes. J Exp Med (1987) 1.39
CD73-deficient mice are resistant to carcinogenesis. Cancer Res (2012) 1.38
Exocytosis of cytolytic granules may not be required for target cell lysis by cytotoxic T-lymphocytes. Nature (1987) 1.37
Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res (2013) 1.36
Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate. Neoplasia (2011) 1.34
Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition. J Immunol (2007) 1.32
Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A (2013) 1.32
Immunomodulatory impact of the A2A adenosine receptor on the profile of chemokines produced by neutrophils. FASEB J (2005) 1.32
Adenosine A2A receptor antagonists: blockade of adenosinergic effects and T regulatory cells. Br J Pharmacol (2008) 1.30
Adenosine up-regulates cyclooxygenase-2 in human granulocytes: impact on the balance of eicosanoid generation. J Immunol (2002) 1.24
The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway. Front Immunol (2012) 1.18
Purinergic signaling during inflammation. N Engl J Med (2013) 1.17
Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother (2011) 1.16
Potentiation of neutrophil cyclooxygenase-2 by adenosine: an early anti-inflammatory signal. J Cell Sci (2005) 1.13
Adenosine acts through an A3 receptor to prevent the induction of murine anti-CD3-activated killer T cells. Int J Cancer (2002) 1.12
Introduction to adenosine receptors as therapeutic targets. Handb Exp Pharmacol (2009) 1.10
Novel investigational adenosine A2A receptor antagonists for Parkinson's disease. Expert Opin Investig Drugs (2009) 1.09
Locus of inhibitory action of cAMP-dependent protein kinase in the antigen receptor-triggered cytotoxic T lymphocyte activation pathway. J Biol Chem (1988) 1.06
Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer. Purinergic Signal (2011) 1.06
Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer. J Mol Med (Berl) (2013) 1.03
Sirtuin-7 inhibits the activity of hypoxia-inducible factors. J Biol Chem (2013) 1.02
Anti-CD73 therapy impairs tumor angiogenesis. Int J Cancer (2013) 1.00
Potential use of an antagonist of cAMP-dependent protein kinase to block inhibition and modulate T-cell receptor-triggered activation of cytotoxic T-lymphocytes. J Pharm Sci (1989) 0.93
Mechanistic, functional and immunopharmacological implications of biochemical studies of antigen receptor-triggered cytolytic T-lymphocyte activation. Immunol Rev (1988) 0.92
Effects of extracellular ATP and adenosine on different thymocyte subsets: possible role of ATP-gated channels and G protein-coupled purinergic receptor. J Immunol (1997) 0.92
In vitro induction of T cells that are resistant to A2 adenosine receptor-mediated immunosuppression. Br J Pharmacol (2008) 0.91
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies. J Immunother (2013) 0.90
Cyclic AMP-dependent protein kinase as a part of the possible down-regulating pathway in the antigen receptor-regulated cytotoxic T lymphocyte conjugate formation and granule exocytosis. Ann N Y Acad Sci (1988) 0.84
Damage control by hypoxia-inhibited AK. Blood (2008) 0.83
Adenosine acts through a novel extracellular receptor to inhibit granule exocytosis by natural killer cells. Biochem Biophys Res Commun (1997) 0.79
Phosphodiesterases as targets for modulating T-cell responses. Handb Exp Pharmacol (2011) 0.78
Response to "Ipilimumab (Yervoy) and the TGN1412 catastrophe". Immunobiology (2011) 0.76